Triomics, a healthcare technology startup, has secured $22 million in Series B funding to advance its artificial intelligence platform designed specifically for oncology. The investment round was led by Battery Ventures, with participation from existing investors including Nexus Venture Partners, Lightspeed, and Y Combinator. Founded in 2021, the company aims to alleviate the administrative burden on cancer centers by automating data-intensive tasks such as clinical trial matching and patient appointment preparation. The funding comes at a time when medical breakthroughs are extending the lives of cancer patients, resulting in complex and lengthy medical records. These files often span thousands of pages, containing physician notes, imaging results, pathology reports, and faxed documents. Reviewing such dense records consumes significant time for healthcare staff and increases the risk of human error. Triomics addresses this challenge by utilizing large language models trained specifically on oncology data to extract and summarize critical information directly within the workflow tools clinicians already use. Co-founder Sarim Khan noted that while general AI agents can produce basic summaries, Triomics distinguishes itself through its specialized training, which has attracted prominent institutions like Memorial Sloan Kettering and Yale Cancer Center. The platform generates verifiable patient summaries that provide oncologists with a concise overview of patient history, effectively reducing the time required for appointment preparation. This efficiency gain is crucial in oncology, where patient histories are uniquely complex and staff burnout is a persistent issue. Furthermore, the system automates the submission of tumor reports to government registries, a mandatory compliance requirement for cancer centers. Initially launched to assist physicians in identifying suitable clinical trials for their patients, Triomics expanded its capabilities as large language model technology evolved. The company previously raised $15 million in Series A funding in mid-2024. Over the last year, the startup has reported rapid growth, quadrupling its enterprise customer base and achieving a tenfold increase in annualized recurring revenue. The competitive landscape for AI in healthcare includes medical scribe solutions like Abridge and Microsoft's Nuance, which focus on transcribing and documenting doctor-patient conversations. However, Triomics differentiates its value proposition by focusing on the synthesis of vast, multi-modal medical records rather than just audio transcription. By reducing the time staff spend on administrative duties, Triomics enables oncologists to dedicate more time to direct patient care. The new funding is expected to support further platform development and expansion into additional oncology centers, reinforcing the company's position as a leader in specialized medical AI.